Invirsa
Manufacturing · Ohio, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1275 Kinnear Rd, Columbus, Ohio, 43212, ...Phone Number
(614) 715-1860Website
www.invirsa.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Invirsa
Invirsa is a biotechnology company focused on developing innovative treatments for ocular conditions associated with DNA damage, particularly through their lead compound INV-102. Their primary target clients include patients suffering from ocular injuries due to sulfur mustard gas and those with diabetic dry eye, a condition that is more severe in diabetic populations. The company has secured a partnership with BARDA to support the development of INV-102, aiming to provide disease-modifying therapeutic options rather than just symptomatic relief. Invirsa's leadership team employs a unique approach to drug development, leveraging extensive knowledge to address significant pharmaceutical challenges.Explore more
Invirsa Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Invirsa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Invirsa has new funding data
Check out if Invirsa is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Invirsa
Click to see if Invirsa had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Invirsa has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Invirsa recently announced quarterly report
Invirsa, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Invirsa launches new products
Recommended Actions
Find VP level buyers at Invirsa
Find more new buyers
Compare Similar Companies to Invirsa
Compare insights from companies similar to Invirsa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Invirsa is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Invirsa is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Invirsa.
Invirsa financials insights
Gather financial insights about Invirsa, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$7.7M
2025
Private Equity
$2.8M
Invirsa Tech Stack
A closer look at the technologies used by Invirsa
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
Executive Move
Invirsa has announced that Phillip Casteel has been appointed as Chief Financial Officer.
Executive Moves
Executive Move
Executive Moves
Invirsa News & Media
Invirsa Completes Enrollment of Phase 1/2a Dry Eye Study
COLUMBUS, Ohio--(BUSINESS WIRE)--Invirsa's first clinical trial, a Phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa's topically administered eyedrop formulation of INV-102, has completed enrollment. Subjects had moderate dry eye and dosing was well tolerated in all groups. The study's design allowed Invirsa to evaluate preliminary efficacy endpoints in 36 patients in the Phase 1 multiple ascending dose portion and 48 patients in a Phase 2 expanInvirsa obtains license from Nationwide Children's Hospital to fight respiratory diseases
(CincyTech) The announcement coincides with Invirsa's securing a $16.9 million contract from the government agency involved in the development of medical countermeasures.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Invirsa
Sign Up For FreeTo access detailed company insights
Invirsa is a biotechnology company focused on developing innovative treatments for ocular conditions associated with DNA damage, particularly through their lead compound INV-102. Their primary target clients include patients suffering from ocular injuries due to sulfur mustard gas and those with diabetic dry eye, a condition that is more severe in... Read More
